|
Name |
3,3a,5,6,9,9a-Hexahydro-1-(1,5-dimethyl-4,5-dihydroxyhexyl)-3a-methyl-7-hydroxycyclopenta[b][1]benzopyran-8(7H)-one
|
| Molecular Formula | C21H32O5 | |
| IUPAC Name* |
1-(5,6-dihydroxy-6-methylheptan-2-yl)-7-hydroxy-3a-methyl-3,5,6,7,9,9a-hexahydrocyclopenta[b]chromen-8-one
|
|
| SMILES |
CC(CCC(C(C)(C)O)O)C1=CCC2(C1CC3=C(O2)CCC(C3=O)O)C
|
|
| InChI |
InChI=1S/C21H32O5/c1-12(5-8-18(23)20(2,3)25)13-9-10-21(4)15(13)11-14-17(26-21)7-6-16(22)19(14)24/h9,12,15-16,18,22-23,25H,5-8,10-11H2,1-4H3
|
|
| InChIKey |
QQLTWWDUOUVAFG-UHFFFAOYSA-N
|
|
| Synonyms |
Tricycloalternarene 6b; 3,3a,5,6,9,9a-Hexahydro-1-(1,5-dimethyl-4,5-dihydroxyhexyl)-3a-methyl-7-hydroxycyclopenta[b][1]benzopyran-8(7H)-one
|
|
| CAS | NA | |
| PubChem CID | 100943922 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 364.5 | ALogp: | 1.4 |
| HBD: | 3 | HBA: | 5 |
| Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 87.0 | Aromatic Rings: | 3 |
| Heavy Atoms: | 26 | QED Weighted: | 0.651 |
| Caco-2 Permeability: | -4.649 | MDCK Permeability: | 0.00001270 |
| Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.08 |
| Human Intestinal Absorption (HIA): | 0.015 | 20% Bioavailability (F20%): | 0.023 |
| 30% Bioavailability (F30%): | 0.004 |
| Blood-Brain-Barrier Penetration (BBB): | 0.115 | Plasma Protein Binding (PPB): | 97.70% |
| Volume Distribution (VD): | 1.939 | Fu: | 2.70% |
| CYP1A2-inhibitor: | 0.071 | CYP1A2-substrate: | 0.618 |
| CYP2C19-inhibitor: | 0.023 | CYP2C19-substrate: | 0.743 |
| CYP2C9-inhibitor: | 0.15 | CYP2C9-substrate: | 0.736 |
| CYP2D6-inhibitor: | 0.039 | CYP2D6-substrate: | 0.541 |
| CYP3A4-inhibitor: | 0.046 | CYP3A4-substrate: | 0.34 |
| Clearance (CL): | 15.387 | Half-life (T1/2): | 0.67 |
| hERG Blockers: | 0.028 | Human Hepatotoxicity (H-HT): | 0.52 |
| Drug-inuced Liver Injury (DILI): | 0.034 | AMES Toxicity: | 0.035 |
| Rat Oral Acute Toxicity: | 0.028 | Maximum Recommended Daily Dose: | 0.107 |
| Skin Sensitization: | 0.59 | Carcinogencity: | 0.107 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
| Respiratory Toxicity: | 0.145 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003123 | ![]() |
0.795 | D02ZGI | ![]() |
0.357 | ||
| ENC003212 | ![]() |
0.695 | D0T2PL | ![]() |
0.277 | ||
| ENC005805 | ![]() |
0.655 | D05BTM | ![]() |
0.267 | ||
| ENC001868 | ![]() |
0.655 | D08SVH | ![]() |
0.267 | ||
| ENC005806 | ![]() |
0.640 | D02VPX | ![]() |
0.261 | ||
| ENC004443 | ![]() |
0.635 | D0L7AS | ![]() |
0.252 | ||
| ENC003577 | ![]() |
0.633 | D0N1TP | ![]() |
0.246 | ||
| ENC003211 | ![]() |
0.544 | D0K5WS | ![]() |
0.233 | ||
| ENC001869 | ![]() |
0.511 | D04VIS | ![]() |
0.221 | ||
| ENC005807 | ![]() |
0.495 | D04ATM | ![]() |
0.219 | ||